Analysis of the Putative Role of CR1 in Alzheimer’s Disease: Genetic Association, Expression and Function
Open accessThe DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Abstract
Chronic activation of the complement system and induced inflammation are associated with neuropathology in Alzheimer's disease (AD). Recent large genome wide association studies (GWAS) have identified single nucleotide polymorphisms (SNPs) in the C3b/C4b receptor (CR1 or CD35) that are associated with late onset AD. Here, anti-CR1 antibodies (Abs) directed against different epitopes of the receptor, were used to localize CR1 in brain, and relative binding affinities of the CR1 ligands, C1q and C3b, were assessed by ELISA. Most Abs tested stained red blood cells in blood vessels but showed no staining in brain parenchyma. However, two monoclonal anti-CR1 Abs labeled astrocytes in all of the cases tested, and this reactivity was preabsorbed by purified recombinant human CR1. Human brain-derived astrocyte cultures were also reactive with both mAbs. The amount of astrocyte staining varied among the samples, but no consistent difference was conferred by diagnosis or the GWAS-identified SNPs rs4844609 or rs6656401. Plasma levels of soluble CR1 did not correlate with diagnosis but a slight increase was observed with rs4844609 and rs6656401 SNP. There was also a modest but statistically significant increase in relative binding activity of C1q to CR1 with the rs4844609 SNP compared to CR1 without the SNP, and of C3b to CR1 in the CR1 genotypes containing the rs6656401 SNP (also associated with the larger isoform of CR1) regardless of clinical diagnosis. These results suggest that it is unlikely that astrocyte CR1 expression levels or C1q or C3b binding activity are the cause of the GWAS identified association of CR1 variants with AD. Further careful functional studies are needed to determine if the variant-dictated number of CR1 expressed on red blood cells contributes to the role of this receptor in the progression of AD, or if another mechanism is involved.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig 1 Representation of CR1 structure, ligand binding sites and location of antibody epitopes. CYT: cytoplasmic domain, TM: transmembrane domain. Red dot indicates location of rs4844609 (Ser1610Thr). Diagram modified from[16]; Antibody reactivity modified from[17].](https://figures.cochat.ai/paper-figures/14cc88966a5949c2bc8a0c8df41edee9/analysis-of-the-putative-role-of-cr1-in-alzheimers-disease-genetic-association-figure-1.jpg)






![Fig 8 Soluble CR1 concentration (ng/ml) in plasma from donors with different CR1 SNPs and diagnosis. Soluble CR1 was measured by ELISA and plotted vs. A. SNP [rs6656401 only (n = 21) or rs6656401 and rs4844609 (n = 16) and without the rs6656401 and rs4844609 SNPs (n = 22)] or B. categorized by diagnosis [nondemented (n = 22),), MCI (n = 14) and AD (n = 19)]. Recombinant CR1 was used to generate the standard curve. Black symbols indicate samples with no variant SNP (rs6656401 and rs4844609), red reflects donors with two SNPs, and blue is donors with rs6656401 only. Data points are from multiple experiments in which samples were run in triplicate and normalized to standard CR1 samples across experiments.](https://figures.cochat.ai/paper-figures/536f20347e134662a8bae02798ccb059/analysis-of-the-putative-role-of-cr1-in-alzheimers-disease-genetic-association-figure-8.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CR1 is predominantly expressed by erythrocytes (343, 344) and A 𝛃 -C3b-CR1-mediated interactions sequester A 𝛃 42 to promote clearance to periphery (180, 338), suggesting that CR1 variants can increase free blood A 𝛃 levels (343), which in turn can promote RAGE-mediated A 𝛃 re-entry across the BBB into the brain.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [180]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Our analyses also nominate alternative candidates at three AD risk loci. First, the association at 1q32.2 has been linked to CR153–55, but we observed a colocalized association for both CR1 and CR2 levels with AD risk (Supp. Fig. 23).”
From Proteogenomic analysis of human cerebrospinal fluid identifies neurologically relevant regulation and implicates causal proteins for Alzheimer’s disease (2024) · cites this paper as [53]
In the citing paper
“expression studies in human brain parenchyma found very modest correlations between CR1 expression and AD-associated CR1 genetic variants (142).”
From Microglia Function in the Central Nervous System During Health and Neurodegeneration (2017) · cites this paper as [142]
In the citing paper
“AD-associated genes include CR1 (complement receptor 1), which plays roles in phagocytosis, clearing of immune complexes, and inhibition of complement (Khera and Das, 2009; Fonseca et al., 2016), and CLU/apoJ, which reportedly can function as an inhibitor of the terminal complement complex (Murphy et al., 1989; Tschopp et al., 1993; McDonald and Nelsestuen, 1997).”
From Microglia in Alzheimer’s disease (2018) · cites this paper as Fonseca et al., 2016
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326
The Classical Complement Cascade Mediates CNS Synapse Elimination
Stevens, B., Allen, N. J., Vazquez, L. E., Howell, G. R., Christopherson, K. S., Nouri, N., Micheva, K. D., Mehalow, A. K., Huberman, A. D., Stafford, B., et al. (2007) · Cell · doi:10.1016/j.cell.2007.10.036 · Cited by 3,313
Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease
the European Alzheimer's Disease Initiative Investigators, Lambert, J.-C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., Combarros, O., Zelenika, D., Bullido, M. J., et al. (2009) · Nature Genetics · doi:10.1038/ng.439 · Cited by 2,234
Integrated Systems Approach Identifies Genetic Nodes and Networks in Late-Onset Alzheimer’s Disease
Zhang, B., Gaiteri, C., Bodea, L.-G., Wang, Z., McElwee, J., Podtelezhnikov, A. A., Zhang, C., Xie, T., Tran, L., Dobrin, R., et al. (2013) · Cell · doi:10.1016/j.cell.2013.03.030 · Cited by 1,657
Weisman, H. F., Bartow, T., Leppo, M. K., Marsh, H. C., Carson, G. R., Concino, M. F., Boyle, M. P., Roux, K. H., Weisfeldt, M. L., & Fearon, D. T. (1990) · Science · doi:10.1126/science.2371562 · Cited by 977
Inflammation in Alzheimer Disease--A Brief Review of the Basic Science and Clinical Literature
Wyss-Coray, T., & Rogers, J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006346 · Cited by 975 · cited 1×
“Detrimental and neuroprotective effects of the complement system have been shown in Alzheimer’s disease as well as other neurodegenerative diseases (reviewed in [39,40].”
BackgroundSelf-citationComplement activation by beta-amyloid in Alzheimer disease.
Rogers, J., Cooper, N. R., Webster, S., Schultz, J., McGeer, P. L., Styren, S. D., Civin, W. H., Brachova, L., Bradt, B., & Ward, P. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.21.10016 · Cited by 817
Self-citationRaff, M., Abney, E., Cohen, J., Lindsay, R., & Noble, M. (1983) · The Journal of Neuroscience · doi:10.1523/jneurosci.03-06-01289.1983 · Cited by 759
Deane, R., Bell, R., Sagare, A., & Zlokovic, B. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709787601867 · Cited by 548
Complement in Immune and Inflammatory Disorders: Pathophysiological Mechanisms
Ricklin, D., & Lambris, J. D. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1203487 · Cited by 478
Jun, G. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.201 · Cited by 422
Human neutrophils increase expression of C3bi as well as C3b receptors upon activation.
Berger, M., O'Shea, J., Cross, A. S., Folks, T. M., Chused, T. M., Brown, E. J., & Frank, M. M. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111572 · Cited by 381
Complement C3-Deficient Mice Fail to Display Age-Related Hippocampal Decline
Shi, Q., Colodner, K. J., Matousek, S. B., Merry, K., Hong, S., Kenison, J. E., Frost, J. L., Le, K. X., Li, S., Dodart, J.-C., et al. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.1698-15.2015 · Cited by 368 · cited 1×
“In contrast, C3 has been shown to have beneficial effects in a mouse model of AD [46], which may be due to the enhancement of clearance of C3b-opsonized amyloid [47].”
BackgroundComplement activation and inhibition: a delicate balance
Sjöberg, A. P., Trouw, L. A., & Blom, A. M. (2009) · Trends in Immunology · doi:10.1016/j.it.2008.11.003 · Cited by 364 · cited 1×
“However, if uncontrolled, inflammation resulting from ongoing and/or chronic complement activation can lead to tissue damage as seen in arthritis, age-related macular degeneration, traumatic brain injury and perhaps Alzheimer’s disease [1,2].”
BackgroundAbsence of C1q Leads to Less Neuropathology in Transgenic Mouse Models of Alzheimer's Disease
Fonseca, M. I., Zhou, J., Botto, M., & Tenner, A. J. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.0901-04.2004 · Cited by 345 · cited 1×
“The detrimental role of C1 has been demonstrated A transgenic model of AD deficient in C1q, and therefore unable to activate complement via the classical pathway, showed less pathology relative to the C1q-sufficient wild type [41].”
BackgroundSelf-citationMaier, M., Peng, Y., Jiang, L., Seabrook, T. J., Carroll, M. C., & Lemere, C. A. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.0829-08.2008 · Cited by 323 · cited 1×
“In contrast, C3 has been shown to have beneficial effects in a mouse model of AD [46], which may be due to the enhancement of clearance of C3b-opsonized amyloid [47].”
BackgroundFonseca, M. I., Ager, R. R., Chu, S.-H., Yazan, O., Sanderson, S. D., LaFerla, F. M., Taylor, S. M., Woodruff, T. M., & Tenner, A. J. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901005 · Cited by 268
Self-citationComplement Receptor Type 1 (CR1, CD35) Is a Receptor for C1q
Klickstein, L. B., Barbashov, S. F., Liu, T., Jack, R. M., & Nicholson-Weller, A. (1997) · Immunity · doi:10.1016/s1074-7613(00)80356-8 · Cited by 257
Structure–function relationships of complement receptor type 1
Krych‐Goldberg, M., & Atkinson, J. P. (2001) · Immunological Reviews · doi:10.1034/j.1600-065x.2001.1800110.x · Cited by 257
Self-citationComplement-dependent Proinflammatory Properties of the Alzheimer's Disease β-Peptide
Bradt, B. M., Kolb, W. P., & Cooper, N. R. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.3.431 · Cited by 255
Corneveaux, J. J., Myers, A. J., Allen, A. N., Pruzin, J. J., Ramirez, M., Engel, A., Nalls, M. A., Chen, K., Lee, W., Chewning, K., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq221 · Cited by 237
Brouwers, N., Van Cauwenberghe, C., Engelborghs, S., Lambert, J.-C., Bettens, K., Le Bastard, N., Pasquier, F., Montoya, A. G., Peeters, K., Mattheijssens, M., et al. (2012) · Molecular Psychiatry · doi:10.1038/mp.2011.24 · Cited by 227 · cited 3×
“Recent studies have found associations of the CR1 SNPs rs6656401 and rs4844609 with AD and cognitive decline [3,15,16], although there is some controversy with respect to the association of memory decline with coding variant rs4844609, Ser1610Thr [30].”
BackgroundMabbott, N. A., Bruce, M. E., Botto, M., Walport, M. J., & Pepys, M. B. (2001) · Nature Medicine · doi:10.1038/86562 · Cited by 224
Localization and Cell Association of C1q in Alzheimer's Disease Brain
Afagh, A., Cummings, B. J., Cribbs, D. H., Cotman, C. W., & Tenner, A. J. (1996) · Experimental Neurology · doi:10.1006/exnr.1996.0043 · Cited by 224
Self-citationComplement Receptor 1: Disease associations and therapeutic implications
Khera, R., & Das, N. (2009) · Molecular Immunology · doi:10.1016/j.molimm.2008.09.026 · Cited by 213
Replication of CLU, CR1, and PICALM Associations With Alzheimer Disease
Carrasquillo, M. M., Belbin, O., Hunter, T. A., Ma, L., Bisceglio, G. D., Zou, F., Crook, J. E., Pankratz, V. S., Dickson, D. W., Graff-Radford, N. R., et al. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.147 · Cited by 208
Fraser, D. A., Pisalyaput, K., & Tenner, A. J. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06494.x · Cited by 196
Self-citationThe complement cascade: Yin-Yang in neuroinflammation—neuro-protection and -degeneration
Alexander, J. J., Anderson, A. J., Barnum, S. R., Stevens, B., & Tenner, A. J. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05668.x · Cited by 177 · cited 2×
“In addition, C1q induces neuroprotective activities, by inducing neuron survival and neuroprotective gene pathways [48–50], binding to apoptotic neurons and cellular debris inducing their clearance and modulating microglial proinflammatory cytokine expression ([51,52] and reviewed in [39].”
BackgroundSelf-citationPeripheral clearance of amyloid β peptide by complement C3-dependent adherence to erythrocytes
Rogers, J., Li, R., Mastroeni, D., Grover, A., Leonard, B., Ahern, G., Cao, P., Kolody, H., Vedders, L., Kolb, W. P., et al. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.09.043 · Cited by 175 · cited 4×
“The colocalization of C3b and CR1 with Aß at the RBC surface is consistent with a role for CR1-mediated clearance of Aß from blood [25] similar to the role of immune adherence in clearing immune complexes from the blood.”
BackgroundMethodInfluentialSelf-citationCR1 is associated with amyloid plaque burden and age‐related cognitive decline
Chibnik, L. B., Shulman, J. M., Leurgans, S. E., Schneider, J. A., Wilson, R. S., Tran, D., Aubin, C., Buchman, A. S., Heward, C. B., Myers, A. J., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22277 · Cited by 174
Fraser, D. A., Laust, A. K., Nelson, E. L., & Tenner, A. J. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0902232 · Cited by 163
Self-citationBenoit, M. E., Hernandez, M. X., Dinh, M. L., Benavente, F., Vasquez, O., & Tenner, A. J. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.400168 · Cited by 155
Self-citationVelázquez, P., Cribbs, D. H., Poulos, T. L., & Tenner, A. J. (1997) · Nature Medicine · doi:10.1038/nm0197-77 · Cited by 154
Self-citationBenoit (2011) · doi:10.1523/jneurosci.3932-10.2011 · Cited by 144
Self-citationPolymorphism of human erythrocyte C3b/C4b receptor.
Dykman, T. R., Cole, J. L., Iida, K., & Atkinson, J. P. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.6.1698 · Cited by 143
Self-citationLemere, C. (2003) · Neurobiology of Disease · doi:10.1016/s0969-9961(03)00044-5 · Cited by 139
Van Den Berge, S. A., Middeldorp, J., Zhang, C. E., Curtis, M. A., Leonard, B. W., Mastroeni, D., Voorn, P., Van De Berg, W. D. J., Huitinga, I., & Hol, E. M. (2010) · Aging Cell · doi:10.1111/j.1474-9726.2010.00556.x · Cited by 119
Self-citationComplement activation in very early Alzheimer disease
Zanjani, H., Finch, C. E., Kemper, C., Atkinson, J., McKeel, D., Morris, J. C., & Price, J. L. (2005) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000165506.60370.94 · Cited by 115
Self-citationIdentification and characterization of complement C3 receptors on human astrocytes
Gasque, P., Chan, P., Mauger, C., Schouft, M. T., Singhrao, S., Dierich, M. P., Morgan, B. P., & Fontaine, M. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.6.2247 · Cited by 106
Pisalyaput, K., & Tenner, A. J. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05012.x · Cited by 103
Self-citationCerebrospinal fluid levels of complement proteins C3, C4 and CR1 in Alzheimer’s disease
Daborg, J., Andréasson, U., Pekna, M., Lautner, R., Hanse, E., Minthon, L., Blennow, K., Hansson, O., & Zetterberg, H. (2012) · Journal of Neural Transmission · doi:10.1007/s00702-012-0797-8 · Cited by 97
Differential expression of individual complement regulators in the brain and choroid plexus.
Singhrao, S. K., Neal, J. W., Rushmere, N. K., Morgan, B. P., & Gasque, P. (1999) · PubMed · Cited by 95
Genetic association of CR1 with Alzheimer's disease: A tentative disease mechanism
Hazrati, L., Cauwenberghe, C. V., Brooks, P. L., Brouwers, N., Ghani, M., Sato, C., Cruts, M., Sleegers, K., George‐Hyslop, P. S., Broeckhoven, C. V., et al. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.07.001 · Cited by 93
A coding variant in CR1 interacts with APOE-ɛ4 to influence cognitive decline
Keenan, B. T., Shulman, J. M., Chibnik, L. B., Raj, T., Tran, D., Sabuncu, M. R., Initiative, T. A. D. N., Allen, A. N., Corneveaux, J. J., Hardy, J. A., et al. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds054 · Cited by 90
C1q and C4b Bind Simultaneously to CR1 and Additively Support Erythrocyte Adhesion
Tas, S. W., Klickstein, L. B., Barbashov, S. F., & Nicholson-Weller, A. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.9.5056 · Cited by 81
Liu, D., & Niu, Z.-X. (2009) · Immunopharmacology and Immunotoxicology · doi:10.3109/08923970902845768 · Cited by 79
Complement activation as a biomarker for Alzheimer's disease
Aiyaz, M., Lupton, M. K., Proitsi, P., Powell, J. F., & Lovestone, S. (2011) · Immunobiology · doi:10.1016/j.imbio.2011.07.023 · Cited by 77
Complement activation in human prion disease
Kovacs, G. G., Gasque, P., Ströbel, T., Lindeck-Pozza, E., Strohschneider, M., Ironside, J. W., Budka, H., & Guentchev, M. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.09.010 · Cited by 72
Pascual, M. A., Duchosal, M. A., Steiger, G., Giostra, E., Pechère, A., Paccaud, J. P., Danielsson, C., & Schifferli, J. A. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.151.3.1702 · Cited by 66
Walker, J. R., Pacoma, R., Watson, J., Ou, W., Alves, J., Mason, D. E., Peters, E. C., Urbina, H. D., Welzel, G., Althage, A., et al. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.3407-12.2013 · Cited by 58
Leonard, B. W., Mastroeni, D., Grover, A., Liu, Q., Yang, K., Gao, M., Wu, J., Pootrakul, D., van den Berge, S. A., Hol, E. M., et al. (2009) · Journal of Comparative Neurology · doi:10.1002/cne.22040 · Cited by 56
Self-citationMapping epitopes for 20 monoclonal antibodies to CR1
Nickells, M. W., Hauhart, R. E., Krych, M., Subramanian, V. B., Geoghegan-Barek, K. M., Marsh, H. C., & Atkinson, J. P. (1998) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.1998.00549.x · Cited by 56
Self-citationElastase and metalloproteinase activities regulate soluble complement receptor 1 release
Sadallah, S., Hess, C., Miot, S., Spertini, O., Lutz, H. U., & Schifferli, J. (1999) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199911)29:11<3754::aid-immu3754>3.0.co;2-5 · Cited by 56
Characterization of glial cultures from rapid autopsies of Alzheimer's and control patients
Lue, L., Brachova, L., Walker, D. G., & Rogers, J. (1996) · Neurobiology of Aging · doi:10.1016/0197-4580(96)00006-1 · Cited by 55
Self-citationMakrides, S. C., Scesney, S. M., Ford, P. J., Evans, K. S., Carson, G. R., & Marsh, H. C. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)35828-9 · Cited by 51
Jacquet, M., Lacroix, M., Ancelet, S., Gout, E., Gaboriaud, C., Thielens, N. M., & Rossi, V. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202451 · Cited by 51
Villiers, M., VILLIERS, C. L., Jacquier‐Sarlin, M. R., Gabert, F. M., Journet, A., & Colomb, M. G. (1996) · Immunology · doi:10.1046/j.1365-2567.1996.d01-747.x · Cited by 48
Alzheimer's disease is associated with low density of the long CR1 isoform
Mahmoudi, R., Kisserli, A., Novella, J., Donvito, B., Dramé, M., Réveil, B., Duret, V., Jolly, D., Pham, B., & Cohen, J. H. M. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.01.006 · Cited by 47
Moldenhauer, F., Botto, M., & Walport, M. J. (1988) · PubMed · Cited by 40
Canova, C., Neal, J. W., & Gasque, P. (2006) · Journal of Neuroinflammation · doi:10.1186/1742-2094-3-22 · Cited by 39
Reference Typing Report for Complement Receptor 1 (CR1)
Moulds, J. M., Brai, M., Cohen, J. H. M., Cortelazzo, A., Cuccia, M., Lin, M., Sadallah, S., Schifferli, J. A., Subramanian, V. B., Truedsson, L., et al. (1998) · Experimental and Clinical Immunogenetics · doi:10.1159/000019084 · Cited by 33
Self-citationMichel, B., Ferguson, A. R., Johnson, T., Bender, H., Meyerett-Reid, C., Pulford, B. E., von Teichman, A., Seelig, D. M., Weis, J. H., Telling, G. C., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1201579 · Cited by 30
Complement receptor 1 coding variant p.Ser1610Thr in Alzheimer's disease and related endophenotypes
Cauwenberghe, C. V., Bettens, K., Engelborghs, S., Vandenbulcke, M., Dongen, J. V., Vermeulen, S., Vandenberghe, R. R., Deyn, P. P. D., Broeckhoven, C. V., & Sleegers, K. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.03.008 · Cited by 27
Mannose-Binding Lectin Binds to Amyloid Protein and Modulates Inflammation
Larvie, M., Shoup, T., Chang, W.-C., Chigweshe, L., Hartshorn, K., White, M. R., Stahl, G. L., Elmaleh, D. R., & Takahashi, K. (2012) · Journal of Biomedicine and Biotechnology · doi:10.1155/2012/929803 · Cited by 26
Tetteh‐Quarcoo, P. B., Schmidt, C. Q., Tham, W., Hauhart, R. E., Mertens, H. D. T., Rowe, A. J., Atkinson, J. P., Cowman, A. F., Rowe, J. A., & Barlow, P. N. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034820 · Cited by 26
Self-citationAntibody CR1-2B11 recognizes a non-polymorphic epitope of human CR1 (CD35)
Chen, C.-H., Ghiran, I. C., Beurskens, F. J. M., Weaver, G., Vincent, J., Nicholson-Weller, A., & Klickstein, L. B. (2007) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2007.03355.x · Cited by 11
Karthikeyan, G., Sivasankar, B., Seth, S., & Das, N. (2006) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-006-9040-5 · Cited by 6
Cited by
Microglia Function in the Central Nervous System During Health and Neurodegeneration
Colonna, M., & Butovsky, O. (2017) · Annual Review of Immunology · doi:10.1146/annurev-immunol-051116-052358 · Cited by 2,894
Blood-Brain Barrier: From Physiology to Disease and Back
Sweeney, M. D., Zhao, Z., Montagne, A., Nelson, A. R., & Zlokovic, B. V. (2019) · Physiological Reviews · doi:10.1152/physrev.00050.2017 · Cited by 2,312
Microglia in Alzheimer’s disease
Hansen, D. V., Hanson, J. E., & Sheng, M. (2018) · Journal of Cell Biology · doi:10.1083/jcb.201709069 · Cited by 1,935
Microglia emerge as central players in brain disease
Salter, M. W., & Stevens, B. (2017) · Nature Medicine · doi:10.1038/nm.4397 · Cited by 1,767
Verkhratsky, A., & Nedergaard, M. (2018) · Physiological Reviews · doi:10.1152/physrev.00042.2016 · Cited by 1,678
Metadata
- Authors
- Fonseca, M. I., Chu, S., Pierce, A. L., Brubaker, W. D., Hauhart, R. E., Mastroeni, D., Clarke, E. V., Rogers, J., Atkinson, J. P., & Tenner, A. J.
- Affiliations
- University of California, Irvine (US)
- SRI International (US)
- Washington University in St. Louis (US)
- Maastricht University Medical Centre (NL)
- Corresponding author
- Tenner, Andrea J.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-02-25
- Volume
- 11
- Issue
- 2
- Pages
- e0149792
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4767815
- OpenAlex
- W2277126095
- Cited by
- 87
- References
- 67
- Citations by year
- 2026: 1 · 2025: 7 · 2024: 7 · 2023: 9 · 2022: 5 · 2021: 10 · 2020: 10 · 2019: 6 · 2018: 15 · 2017: 14 · 2016: 3
- FWCI
- 10.19
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, cc-by)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Funders
- Northwestern University
- National Institutes of Health (AG00538, AG16573)
- National Institute on Aging (P01AG000538, R01AG039750, P50 AG 16573, AG 16573, AG007367, AG039750, AG 00538, P50AG016573, R01AG007367, R56AG007367)
- National Institute of Allergy and Infectious Diseases (R01AI041592)
- National Institute of Neurological Disorders and Stroke (R01NS035144, NS35144)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (P30AR048335)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- complement receptor 1, Alzheimer's disease, late-onset Alzheimer's disease, single nucleotide polymorphisms, C1q binding, C3b binding, astrocytes, soluble CR1, complement system, neuroinflammation, genetic association
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Astrocytes, Brain, Complement C3b, Erythrocytes, Female, Gene Expression Regulation, Humans, Male, Complement C1q, Receptors, Complement 3b, Genetic Predisposition to Disease, Polymorphism, Single Nucleotide, Protein Transport
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.